Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

Background/Aims Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC from the LUCENT-1 and LUCENT-2 studies. Methods LU...

Full description

Bibliographic Details

Published in:	Intestinal Research
Main Authors:	Taku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, Tadakazu Hisamatsu, Fumihito Hirai, Joe Milata, Xingyuan Li, Nathan Morris, Vipin Arora, Tomoko Ishizuka, Koji Matsuo, Yoichi Satoi, Catherine Milch, Toshifumi Hibi
Format:	Article
Language:	English
Published:	Korean Association for the Study of Intestinal Diseases 2024-04-01
Subjects:	bowel urgency interleukin-23 p19 japan mirikizumab ulcerative colitis
Online Access:	http://irjournal.org/upload/pdf/ir-2023-00043.pdf